Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Verneuil Vanina De Sells 1,403 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Verneuil Vanina De sold 1,403 shares of Vir Biotechnology stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $7.20, for a total transaction of $10,101.60. Following the completion of the transaction, the executive vice president now directly owns 63,717 shares of the company’s stock, valued at $458,762.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Verneuil Vanina De also recently made the following trade(s):

• On Tuesday, November 5th, Verneuil Vanina De sold 2,347 shares of Vir Biotechnology stock. The stock was sold at an average price of $9.47, for a total transaction of $22,226.09.

Vir Biotechnology Price Performance

Shares of VIR opened at $9.64 on Wednesday. Vir Biotechnology, Inc. has a one year low of $7.12 and a one year high of $13.09. The stock’s fifty day moving average is $7.77 and its 200-day moving average is $8.88.

Vir Biotechnology (NASDAQ:VIR) last released its earnings results on Thursday, October 31st. The company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($1.05) by ($0.51). The company had revenue of $2.38 million for the quarter, compared to analyst estimates of $5.54 million. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The firm’s quarterly revenue was down 9.8% on a year-over-year basis. During the same period in the previous year, the business posted ($1.22) EPS. Research analysts anticipate that Vir Biotechnology, Inc. will post -3.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vir Biotechnology

Institutional investors have recently added to or reduced their stakes in the company. Texas Permanent School Fund Corp lifted its holdings in Vir Biotechnology by 1.4% in the 1st quarter. Texas Permanent School Fund Corp now owns 74,977 shares of the company’s stock valued at $760,000 after acquiring an additional 1,012 shares during the last quarter. Louisiana State Employees Retirement System boosted its holdings in Vir Biotechnology by 2.8% during the second quarter. Louisiana State Employees Retirement System now owns 43,800 shares of the company’s stock worth $390,000 after buying an additional 1,200 shares in the last quarter. ProShare Advisors LLC grew its position in Vir Biotechnology by 8.4% in the first quarter. ProShare Advisors LLC now owns 26,392 shares of the company’s stock worth $267,000 after buying an additional 2,035 shares during the last quarter. Blue Trust Inc. grew its position in Vir Biotechnology by 143.5% in the third quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock worth $30,000 after buying an additional 2,351 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Vir Biotechnology by 15.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 24,647 shares of the company’s stock valued at $219,000 after buying an additional 3,215 shares in the last quarter. 65.32% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on VIR shares. HC Wainwright reiterated a “buy” rating and set a $110.00 price target on shares of Vir Biotechnology in a research report on Monday. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 target price on shares of Vir Biotechnology in a research note on Friday, November 1st. Finally, Barclays lowered their price target on shares of Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Monday. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $36.40.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).